Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
As-needed budesonide-formoterol versus as-needed salbutamol for mild childhood asthma
ACTRN12620001091998Phase 3Completed
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide, formoterol and salbutamol in asthma (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Asthma attacks rate. Started Jan 2021; status: completed.
02
Drugs
budesonideformoterolsalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12620001091998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001091998.